Genscript Biotech Corp Faces Renewed Scrutiny Over Ties to China

Genscript Biotech Corp, a biotech service company based in Nanjing, China, is once again under the spotlight as U.S. lawmakers renew concerns about its ties to China. The company, which offers life science services, products, and pre-clinical drug development services, is listed on the Hong Kong Stock Exchange.

Recent Developments

On July 8, 2025, the U.S. House of Representatives committee on China sent a letter to the directors of the FBI and national intelligence, expressing renewed concerns about GenScript Biotechnology’s interactions with U.S. companies. The letter, which was reported by Reuters, was authored by committee chair John Moolenaar and ranking member Raja Krishnamoorthi. They requested updated intelligence and law enforcement information regarding GenScript and its affiliates, including Bestzyme, Legend, and ProBio.

This development follows a similar request last year, during the administration of former President Joe Biden, where lawmakers sought a briefing on whether the Chinese Communist Party had influence over GenScript’s operations and its role in advancing China’s biotech capabilities. The previous inquiry led to a significant drop in GenScript’s share price, with a decline of up to 25% in Hong Kong.

Market Impact

As of July 6, 2025, GenScript’s close price was HKD 14.64, with a 52-week high of HKD 17.78 on June 10, 2025, and a 52-week low of HKD 8.84 on July 9, 2024. The renewed scrutiny from U.S. lawmakers could potentially impact the company’s market performance, given the historical context of share price volatility following similar concerns.

Broader Context

In recent years, U.S. lawmakers have increasingly highlighted the potential threats posed by Contract Development and Manufacturing Organizations (CDMOs) with operations in China. These concerns stem from fears that such firms could be influenced by the Chinese government, thereby posing risks to U.S. national security and biotech capabilities.

For more information on GenScript Biotech Corp’s offerings, visit their website at www.genscript.com .